Literature DB >> 11793615

Peripheral neuropathy associated with fluoroquinolones.

J S Cohen1.   

Abstract

OBJECTIVE: To survey cases of fluoroquinolone-associated adverse events that included peripheral nervous system (PNS) symptoms posted on Internet Web sites.
METHODS: Cases were obtained with the assistance of members of Web sites formed by people sustaining fluoroquinolone-related events. Information obtained met the standards of MedWatch, and each reported case was assessed using the Naranjo probability scale.
RESULTS: In contrast to previous reports suggesting that fluoroquinolone-associated PNS events are mild and short-term, 36 of the 45 cases reported severe events that typically involved multiple organ systems. Although many newer cases are still evolving, symptoms had lasted more than three months in 71% of cases and more than one year in 58%. Onset of adverse events was usually rapid, with 15 (33%) events beginning within 24 hours of initiating treatment, 26 (58%) within 72 hours, and 38 (84%) within one week. Sixty courses of fluoroquinolones were prescribed: levofloxacin (n = 33 cases), ciprofloxacin (n = 11), ofloxacin (n = 6), lomefloxacin (n = 1), trovafloxacin (n = 1); in eight cases the same antibiotic was prescribed twice.
CONCLUSIONS: These cases suggest a possible association between fluoroquinolone antibiotics and severe, long-term adverse effects involving the PNS as well as other organ systems. The severity of these cases may reflect a different population than typically reported to drug companies or MedWatch, which often originate from healthcare providers. In contrast, Internet Web sites may provide a forum for patients experiencing adverse effects that have not resolved promptly. Further study is warranted. Meanwhile the occurrence of PNS symptoms during fluoroquinolone therapy should prompt immediate discontinuation of the agent used.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11793615     DOI: 10.1345/aph.1Z429

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  18 in total

1.  Effects of ciprofloxacin-containing antimicrobial scaffolds on dental pulp stem cell viability-In vitro studies.

Authors:  Krzysztof Kamocki; Jacques E Nör; Marco C Bottino
Journal:  Arch Oral Biol       Date:  2015-05-16       Impact factor: 2.633

2.  Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections.

Authors:  Fang-Yi Su; Selvi Srinivasan; Brian Lee; Jasmin Chen; Anthony J Convertine; Timothy Eoin West; Daniel M Ratner; Shawn J Skerrett; Patrick S Stayton
Journal:  J Control Release       Date:  2018-08-09       Impact factor: 9.776

3.  Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.

Authors:  Beatrice Alexandra Golomb; Hayley Jean Koslik; Alan J Redd
Journal:  BMJ Case Rep       Date:  2015-10-05

4.  Comparative pharmacokinetics and bioavailability of gemifloxacin administered as an intravenous 200 mg formulation or an oral 320 mg tablet.

Authors:  Mi Jo Kim; Hyeong-Seok Lim; Sang-Heon Cho; Kyun-Seop Bae
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

5.  Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones during Hospitalization.

Authors:  William C Frankel; Barbara W Trautner; Andrew Spiegelman; Larissa Grigoryan; Scott A LeMaire
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

6.  Unexpected, severe central nerve system toxicity of ofloxacine: report of two cases.

Authors:  E Oguz Guven; Derya Balbay; Mete Kilciler
Journal:  Int Urol Nephrol       Date:  2007-01-31       Impact factor: 2.370

7.  Permanent Peripheral Neuropathy: A Case Report on a Rare but Serious Debilitating Side-Effect of Fluoroquinolone Administration.

Authors:  Jacquelyn K Francis; Elizabeth Higgins
Journal:  J Investig Med High Impact Case Rep       Date:  2014-07-27

8.  A Severe Accident Caused by an Ocellate River Stingray (Potamotrygon motoro) in Central Brazil: How Well Do We Really Understand Stingray Venom Chemistry, Envenomation, and Therapeutics?

Authors:  Nelson Jorge da Silva; Kalley Ricardo Clementino Ferreira; Raimundo Nonato Leite Pinto; Steven Douglas Aird
Journal:  Toxins (Basel)       Date:  2015-06-18       Impact factor: 4.546

Review 9.  Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications.

Authors:  Krzysztof Michalak; Aleksandra Sobolewska-Włodarczyk; Marcin Włodarczyk; Justyna Sobolewska; Piotr Woźniak; Bogusław Sobolewski
Journal:  Oxid Med Cell Longev       Date:  2017-09-25       Impact factor: 6.543

Review 10.  Kynurenine Aminotransferase Isozyme Inhibitors: A Review.

Authors:  Alireza Nematollahi; Guanchen Sun; Gayan S Jayawickrama; W Bret Church
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.